MX2009004763A - Moduladores aloestericos del receptor de adenosina a1. - Google Patents

Moduladores aloestericos del receptor de adenosina a1.

Info

Publication number
MX2009004763A
MX2009004763A MX2009004763A MX2009004763A MX2009004763A MX 2009004763 A MX2009004763 A MX 2009004763A MX 2009004763 A MX2009004763 A MX 2009004763A MX 2009004763 A MX2009004763 A MX 2009004763A MX 2009004763 A MX2009004763 A MX 2009004763A
Authority
MX
Mexico
Prior art keywords
adenosine receptor
formula
allosteric modulators
compounds
pain
Prior art date
Application number
MX2009004763A
Other languages
English (en)
Inventor
Pier Giovanni Baraldi
Allan R Moorman
Romeo Romagnoli
Original Assignee
King Pharmaceuticals Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/938,514 external-priority patent/US7897596B2/en
Priority claimed from US11/938,465 external-priority patent/US7855209B2/en
Application filed by King Pharmaceuticals Res & Dev filed Critical King Pharmaceuticals Res & Dev
Publication of MX2009004763A publication Critical patent/MX2009004763A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I), en donde R1, R2, R3, R4 y Q, tienen un significado como se define aquí en la especificación. Los compuestos de fórmula (I), son moduladores alostéricos del receptor de adenosina A1, y de este modo, pueden ser empleados para el tratamiento de condiciones mediadas por el receptor de adenosina A1. Por consiguiente, los compuestos de fórmula (I), pueden ser empleados para el tratamiento de dolor en particular, dolor crónico tal como dolor neuropático, enfermedad o trastorno cardiaco, tal como disaritmias cardiacas, por ejemplo, taquicardia supraventricular peroxismal, angina, infarto al miocardio y apoplejía, enfermedad o lesión neurológica, trastornos del sueño, epilepsia y depresión.
MX2009004763A 2006-11-13 2007-11-13 Moduladores aloestericos del receptor de adenosina a1. MX2009004763A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85850506P 2006-11-13 2006-11-13
US11/938,514 US7897596B2 (en) 2006-11-13 2007-11-12 Allosteric modulators of the A1 adenosine receptor
US11/938,465 US7855209B2 (en) 2006-11-13 2007-11-12 Allosteric modulators of the A1 adenosine receptor
PCT/US2007/084490 WO2008063984A2 (en) 2006-11-13 2007-11-13 Allosteric modulators of the a1 adenosine receptor

Publications (1)

Publication Number Publication Date
MX2009004763A true MX2009004763A (es) 2009-05-21

Family

ID=39430473

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004763A MX2009004763A (es) 2006-11-13 2007-11-13 Moduladores aloestericos del receptor de adenosina a1.

Country Status (9)

Country Link
EP (1) EP2081575A4 (es)
JP (1) JP2010509402A (es)
KR (1) KR20090112627A (es)
AU (1) AU2007323888A1 (es)
BR (1) BRPI0718520A2 (es)
CA (1) CA2669447A1 (es)
IL (1) IL198402A0 (es)
MX (1) MX2009004763A (es)
WO (1) WO2008063984A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739588B (zh) * 2014-01-04 2015-07-01 新发药业有限公司 一种2-氨基噻吩衍生物的简便合成方法
US10434099B2 (en) 2016-09-22 2019-10-08 The National Institute for Biotechnology in the Negev Ltd. Methods for treating central nervous system disorders using VDAC inhibitors
AU2016325108B2 (en) * 2015-09-14 2020-10-22 The National Institute for Biotechnology in the Negev Ltd. Novel piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction
US10787423B2 (en) 2015-09-14 2020-09-29 The National Institute For Biotechnolgy In The Negev Ltd. Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction
EP3600290A4 (en) 2017-03-21 2020-08-12 Temple University - Of The Commonwealth System of Higher Education NEW SIGMA 2 RECEIVER MODULATORS AND THEIR OPERATING PROCEDURE
WO2018175190A1 (en) 2017-03-21 2018-09-27 Temple University-Of The Commonwealth System Of Higher Education 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332732A (en) * 1992-09-11 1994-07-26 Mcneilab, Inc. Thiophene and pyridine antipsychotic agents
ES2092737T3 (es) * 1992-10-29 1996-12-01 Hoechst Ag Procedimiento para la preparacion de compuestos bromometil-aromaticos.
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor

Also Published As

Publication number Publication date
WO2008063984A2 (en) 2008-05-29
CA2669447A1 (en) 2008-05-29
WO2008063984A3 (en) 2008-08-14
BRPI0718520A2 (pt) 2013-11-19
KR20090112627A (ko) 2009-10-28
IL198402A0 (en) 2010-02-17
EP2081575A4 (en) 2010-01-06
EP2081575A2 (en) 2009-07-29
AU2007323888A1 (en) 2008-05-29
JP2010509402A (ja) 2010-03-25

Similar Documents

Publication Publication Date Title
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
MX2009004763A (es) Moduladores aloestericos del receptor de adenosina a1.
UA103198C2 (en) Squaramide derivatives as cxcr2 antagonists
MX2010001446A (es) Derivados de 6-amino-pirimidina-4-carboxamida y compuestos relacionados que se enlazan a los receptores para esfingosina 1-fosfato (s1p) para el tratamiento de esclerosis multiple.
TW200745037A (en) Organic compounds
EA200870470A1 (ru) Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2009043889A3 (en) Oxadiazole derivatives
WO2010045258A3 (en) Spirocyclic gpr40 modulators
MX2010003614A (es) Compuestos de diarilo oxadiazol.
PL2303330T3 (pl) Kompozycje farmaceutyczne do leczenia choroby Parkinsona
MX2011006334A (es) Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c] [1,2]-oxaborol-1-ol.
IL209896A0 (en) Compounds for treating symptoms associated with parkinson's disease
EA201001404A1 (ru) Амиды 5-оксо-2,3,4,5-тетрагидробензо[b]оксепин-4-карбоновой кислоты и амиды 2,3-дигидробензо[b]оксепин-4-карбоновой кислоты для лечения и предотвращения диабета 1 и 2 типа
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
WO2008059370A8 (en) Substituted bicyclocarboxyamide compounds
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
WO2010042925A3 (en) Compositions and methods for treating alcohol use disorders, pain and other diseases
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
WO2008045371A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
IL208732A (en) Methods for producing morphogenetic protein of bones number 2 bmp
MA33190B1 (fr) Composes pour le traitement de troubles metaboliques
EP2749554A3 (en) 2,5-disubstituted arylsulfonamide CCR3 antagonists

Legal Events

Date Code Title Description
FA Abandonment or withdrawal